Aurobindo Pharma


Concise Prescribing Info
Venlafaxine HCl
Depression including depression associated w/ anxiety. Generalized anxiety disorder (GAD) including long-term treatment. Social anxiety disorder (SAD) or social phobia. Panic disorder including prevention of relapse.
Dosage/Direction for Use
Major depressive disorder Initially 75 mg once daily, may be increased up to max: 225 mg daily. Dose can be titrated up to 225 mg daily in moderate depression & 375 mg daily in severe depression. GAD Initially 75 mg once daily, may be increased up to max: 225 mg daily. SAD Initially 75 mg once daily. Panic disorder Initially 37.5 mg daily for 7 days, then increased to 75 mg daily. May be further increased up to max: 225 mg daily.
Should be taken with food: Take at the same time each day. Swallow whole, do not chew/crush/divide/dissolve. Cap may be carefully opened & entire contents sprinkled on a spoonful of applesauce. Swallow drug/food mixt w/o chewing immediately after prep & followed w/ glass of water.
Hypersensitivity. Concomitant use or w/in at least 14 days after discontinuation of MAOIs. Discontinue use for at least 7 days before initiating MAOI.
Special Precautions
Monitor for clinical worsening, suicidal behavior or thoughts & unusual behavior changes. Discontinue use if seizures develops. History of MI or unstable heart disease, high risk of serious cardiac arrhythmia; history of convulsions; vol-depleted patients; increased risk of haemorrhage, patients predisposed to bleeding; history of bipolar disorder or aggression; akathisia/psychomotor restlessness; dry mouth; diabetes. Closely monitor patients w/ raised IOP or at risk for acute narrow-angle glaucoma. Monitor BP, control preexisting HTN in BP or heart rate compromised patients. Measure serum cholesterol in long-term use. Ensure appropriate dental hygiene. Avoid abrupt discontinuation. Not recommended in concomitant use w/ serotonin precursors; wt loss agents. Concomitant use w/ diuretics; anticoagulants, platelet inhibitors. May affect ability to drive & use machines. Renal or hepatic impairment. Pregnancy & lactation. Not to be used in childn & adolescents <18 yr. Elderly.
Adverse Reactions
Insomnia; headache, dizziness, sedation; nausea, dry mouth, constipation; hyperhidrosis. Decreased appetite; confusional state, depersonalization, abnormal dreams, nervousness, decreased libido, agitation, anorgasmia; akathisia, tremor, paraesthesia, dysgeusia; visual impairment, accommodation disorder, blurred vision, mydriasis; tinnitus; tachycardia, palpitations; HTN, hot flush; dyspnoea, yawning; diarrhoea, vomiting; rash, pruritus; hypertonia; urinary hesitation & retention, pollakiuria; menorrhagia, metrorrhagia, erectile dysfunction, ejaculation disorder; fatigue, asthenia, chills; decreased/increased wt, increased blood cholesterol.
Drug Interactions
Severe AR w/ MAOIs. Serotonin syndrome w/ other serotonergic agents eg, triptans, SSRIs, SNRIs, lithium, sibutramine, St. John's wort, fentanyl & its analogues, tramadol, dextromethorphan, tapentadol, pethidine, meperidine, methadone, pentazocine; drugs impairing serotonin metabolism eg, methylene blue; serotonin precursors eg, tryptophan supplements; antipsychotics or other dopamine antagonists. Increased levels w/ CYP3A4 inhibitors eg, atazanavir, clarithromycin, indinavir, itraconazole, voriconazole, posaconazole, ketoconazole, nelfinavir, ritonavir, saquinavir, telithromycin. Increased AUC & Cmax of haloperidol. Increased AUC of risperidone. Avoid use w/ alcohol. Caution w/ imipramine, metoprolol. CNS-active drugs.
MIMS Class
ATC Classification
N06AX16 - venlafaxine ; Belongs to the class of other antidepressants.
Binoven-ER cap 37.5 mg
Binoven-ER cap 150 mg
Binoven-ER cap 75 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in